Figure 4.

ASTX660 combined with XRT and PD-1 blockade significantly delays or prevents tumor growth. (A) 5 × 10⁶ MOC1 cells were implanted into the right hind leg of wildtype female C57BL/6 mice. Mice were randomized into 5 groups (vehicle control, daily ASTX660, 2 doses of XRT, ASTX660+XRT, or ASTX660+XRT with anti-PD-1 antibody twice weekly) of 11 mice each starting 12 days after tumor inoculation. ASTX660 treatment began on day 12 with daily treatments via oral gavage for two full weeks with one week off in between (orange arrows). XRT was given in two doses of 8 Gy each on days 2 and 4 of treatment (brown arrows). Anti-PD-1 antibody was given twice weekly (blue arrows). A more detailed treatment schema is available in Supplementary Figure S3B. Error bars represent standard error of the mean. **p < 0.01 versus control, #p < 0.01 versus ASTX660 or XRT only, ⁺ p < 0.05 versus ASTX660+XRT without anti-PD-1. (B) Kaplan-Meier survival curves representing each treatment group.